In the reserpine-induced fibromyalgia rat model, targeting the microglial P2X7R using its antagonist Brilliant Blue G attenuated microglial activation and consequently the production of pain proinflammatory mediators (IL-1β, IL-18), resulting in inhibiting neuroinflammation and fibromyalgia-mediated pain sensitization (D’amico et al. 2021). Here, IL18 is linked to fibromyalgia.